Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready
Gencurix Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 3 distinct examiners and 2 distinct art units. This distribution shows that while each action is handled by a different examiner, two of the actions are likely within the same technical group at the USPTO. Such a spread indicates that the company is pursuing multiple technical paths that require specialized review from different segments of the USPTO.
SITTON, JEHANNE SOUAYA is the busiest examiner for this portfolio, with 1 pending office action. This examiner manages one-third of the company's total pending actions. With 2 distinct art units involved, the prosecution of these 3 actions may encounter different examination standards or timelines despite all falling under the broader Biotechnology & Pharmaceuticals category. Practitioners should be prepared for varied feedback across these matters, as the involvement of 3 distinct examiners and 2 distinct art units reduces the likelihood of a uniform prosecution experience.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SITTON, JEHANNE SOUAYA | 1 | 53.2% | +48.0% |
| SCHLOOP, ALLISON ELIZABETH | 1 | 63.0% | +56.5% |
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 31d overdue |
| 17795848 | COMPOSITION USING CPG METHYLATION CHANGES IN SPECIFIC GENES TO DIAGNOSE BLADDER CANCER, AND USE THEREOF | SALMON, KATHERINE D | 47d |
| 17995685 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER, OR COLORECTAL ADENOMA USING CPG METHYLATION CHANGE OF GLRB GENE, AND USE THEREOF | SCHLOOP, ALLISON ELIZABETH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 31d overdue |
| 17795848 | COMPOSITION USING CPG METHYLATION CHANGES IN SPECIFIC GENES TO DIAGNOSE BLADDER CANCER, AND USE THEREOF | SALMON, KATHERINE D | 47d |
| 17995685 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER, OR COLORECTAL ADENOMA USING CPG METHYLATION CHANGE OF GLRB GENE, AND USE THEREOF | SCHLOOP, ALLISON ELIZABETH | — |
| Art Unit | Apps |
|---|---|
| 1682 | 2 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18030515 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER OR COLORECTAL ADENOMA BY USING CPG METHYLATION CHANGE OF LINC01798 GENE, AND USE THEREOF | SITTON, JEHANNE SOUAYA | 1682 | §101§112 | Final Rejection | 31d overdue | Pending | Apr 06, 2023 |
| 17995685 | COMPOSITION FOR DIAGNOSING COLORECTAL CANCER, RECTAL CANCER, OR COLORECTAL ADENOMA USING CPG METHYLATION CHANGE OF GLRB GENE, AND USE THEREOF | SCHLOOP, ALLISON ELIZABETH | 1683 | §101§103§112 | Final Rejection | — | Pending | Oct 06, 2022 |
| 17795848 | COMPOSITION USING CPG METHYLATION CHANGES IN SPECIFIC GENES TO DIAGNOSE BLADDER CANCER, AND USE THEREOF | SALMON, KATHERINE D | 1682 | §101§112 | Final Rejection | 47d | Pending | Jul 27, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial